表紙
市場調査レポート

世界の乳がん市場

Global Breast Cancer Market Report: 2015 Edition

発行 Koncept Analytics 商品コード 204467
出版日 ページ情報 英文 64 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
世界の乳がん市場 Global Breast Cancer Market Report: 2015 Edition
出版日: 2015年08月11日 ページ情報: 英文 64 Pages
概要

乳がんは、最も頻繁に診断されるがんで、女性のがんによる死亡原因の第1位です。乳がんの最も一般的な危険因子は、女性であることと、加齢です。

当レポートでは、世界の乳がん診断・治療市場について調査分析し、米国、ブラジル、欧州、アジア太平洋地域に焦点を当てて、市場力学、成長促進要因と課題、競合情勢、主要企業などについて、体系的な情報を提供しています。

第1章 市場概要

  • 乳がん
  • 乳がんの種類
  • 危険因子
  • 乳がんの症状
  • 乳がんの診断と治療
    • 乳がんの検査・診断法
    • 乳がんの治療法

第2章 乳がん市場

  • 世界市場
    • 診断市場
    • 治療市場
    • 市場区分

第3章 地域市場

  • 米国
  • ブラジル
  • アジア太平洋地域
  • 欧州

第4章 市場力学

  • 業界の発展
  • 成長促進要因
  • 課題

第5章 競合情勢

  • 医薬品の比較
  • 純利益
  • R&D予算

第6章 企業プロファイル

  • 事業概要、財務概要、事業戦略
    • Johnson & Johnson
    • Hologic, Inc.
    • Roche
    • Novartis
    • Siemens AG

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women. Breast cancer knows no boundaries be it age, gender, socioeconomic status or geographic location. The most common risk factors for breast cancer are being female and growing older.

In the past few years, the cases of breast cancer have increased tremendously in regions like the US and the Europe. The breast cancer market is driven by various factors like aging female population, obesity and diabetes, dense breast tissues, healthcare expenditure, exposure to X-Ray and Gamma Radiations, Estrogen-Progestin Therapy (EPT) and increased consumption of alcohol and tobacco. A major trend which will probably remain eternally in the breast cancer treatment industry is the fact that novel and innovative technologies and pharmaceutical molecules are always under development. Challenges associated with breast cancer are like, financial burdens associated with the treatment and adverse effects of Aromatase Inhibitors (AI) on patients.

The market for breast cancer drugs represents an area of potential opportunity in both developed and developing countries. Due to effectiveness and advancements in technology, a large number of companies are focusing to develop innovative breast cancer drugs. Further, the companies are forming alliances and agreements to develop effective treatment methods for breast cancer.

The present report provides a comprehensive analysis of the global breast cancer diagnosis and treatment market with focus on regions like the US, Brazil, Europe and APAC Countries. Furthermore, market dynamics such as the industry trends and development, the underlying growth drivers and major issues faced by the industry are elicited. On the contention front, the market is personified by the intense competition in terms of research and development of novel therapeutic molecules. The leading players operating in the industry include Hologic, Johnson and Johnson, Siemens AG, Roche and Novartis which are also profiled in this report.

Table of Contents

1. Market Overview

  • 1.1. Breast Cancer
  • 1.2. Types of Breast Cancer
  • 1.3. Risk Factors
  • 1.4. Symptoms of Breast Cancer
  • 1.5. Diagnosis and Treatment of Breast Cancer
    • 1.5.1. Breast Cancer Screening and Diagnostic Measures
    • 1.5.2. Breast Cancer Treatment

2. Breast Cancer Market

  • 2.1. Global Market
    • Diagnostics Market
    • Therapeutic Market
    • Market Segmentation

3. Regional Markets

  • 3.1. The U.S. Breast Cancer Market
    • 3.1.1. The U.S. Breast Cancer Diagnostics Market
    • 3.1.2. The U.S. Breast Cancer Therapeutic Market
    • 3.1.3. The U.S. Metastatic Breast Cancer Market
  • 3.2. Brazilian Breast Cancer Market
    • 3.2.1. Brazilian Breast Cancer Diagnostic Market
    • 3.2.2. Brazilian Breast Cancer Therapeutic Market
  • 3.3. APAC Countries
    • 3.3.1. APAC Diagnostic Market
    • 3.3.2. APAC Therapeutic Market
  • 3.4. European Breast Cancer Market
    • 3.4.1. European Breast Cancer Diagnostic Market
    • 3.4.2. European Metastatic Breast Cancer Market

4. Market Dynamics

  • 4.1. Industry Developments
    • 4.1.1. Introduction of New Drugs & Therapies
    • 4.1.2. Development of Scintimammography for Molecular Breast Imaging
    • 4.1.3. Compounds under Study to Reduce Breast Cancer
    • 4.1.4. Researches on DCIS Prediction
  • 4.2. Growth Drivers
    • 4.2.1. Increasing Use of Tobacco and Alcohol
    • 4.2.2. Increasing Diabetic and Obese Population Worldwide
    • 4.2.3. Rising Healthcare Expenditure
    • 4.2.4. Growing Women Population (Over 45 Years)
    • 4.2.5. Increasing Global Spending on Medicines
    • 4.2.6. Dense Breast Tissue
    • 4.2.7. Exposure to X-Ray and Gamma Radiations
    • 4.2.8. Estrogen-Progestin Therapy (EPT)
  • 4.3. Challenges
    • 4.3.1. Financial Burden of Breast Cancer
    • 4.3.2. Adverse Effects of Aromatase Inhibitors (AI)

5. Competitive Landscape

  • Comparison of Drugs
  • Net Income
  • R&D Budget

6. Company Profiles

  • 6.1. Johnson & Johnson
    • 6.1.1. Business Overview
    • 6.1.2. Financial Overview
    • 6.1.3. Business Strategies
  • 6.2. Hologic, Inc.
    • 6.2.1. Business Overview
    • 6.2.2. Financial Overview
    • 6.2.3. Business Strategies
  • 6.3. Roche
    • 6.3.1. Business Overview
    • 6.3.2. Financial Overview
    • 6.3.3. Business Strategies
  • 6.4. Novartis
    • 6.4.1. Business Overview
    • 6.4.2. Financial Overview
    • 6.4.3. Business Strategies
  • 6.5. Siemens AG
    • 6.5.1. Business Overview
    • 6.5.2. Financial Overview
    • 6.5.3. Business Strategies

List of Charts

  • Types of Breast Cancer
  • Various Biopsy Methods
  • Global Oncology Drug Spending (2010-2014)
  • Global Oncology Spending By Region (2014)
  • Global Breast Cancer Predictive Diagnostic and Drug Technologies (2014 /2019E)
  • Global Breast Cancer Therapeutic Market (2014 /2018E)
  • Global Breast Cancer Market by Segments (2014E)
  • Cases of Breast Cancer in the U.S. by Stage
  • Breast Cancer Deaths by Age Group in the U.S.
  • The U.S. Breast Imaging Systems Market (2010-2016E)
  • The U.S. Digital Mammography Market (2010-2014)
  • Breast Cancer Therapeutic Market in Major Regions (2014E)
  • The U.S. Metastatic Breast Cancer Market Revenues (2011-2015E)
  • Breast Cancer Mortality Rates in Brazil (2008-2014E)
  • Brazil's Breast Cancer Imaging Market (2011-2015E)
  • Brazilian Breast Cancer Drugs Market (2009-2014E)
  • APAC - Tomography Scanners per Million People (2014)
  • APAC - MRI Units per Million People (2014)
  • APAC - Mammography Units per Million Females (2014)
  • APAC Countries Therapeutic Market Share (2014E)
  • The European Breast Imaging Systems Market (2013-2018E)
  • The European Mammography Systems Market (2013-2018E)
  • European Metastatic Breast Cancer Market Revenues (2011-2015E)
  • Global Cigarettes Consumption (1910-2014)
  • Global Diabetic Population (2007-2014E)
  • Global Obese Population (2009-2014)
  • Global Healthcare Expenditure Per Capita (2009-2014E)
  • Global Female Population, Over 45 Years (2008-2014E)
  • Global Spending on Medicines (2007-2017E)
  • Net Income Comparison of Leading Companies (2014)
  • R&D Budgets of Top Companies (2014)
  • Johnson & Johnson Revenue by Business Segments (2014)
  • Johnson & Johnson's Revenue and Net Income (2010-2014)
  • Hologic's Revenue by Business Segment (2014)
  • Hologic's Revenue and Net Income (2010-2014)
  • Roche's Revenue by Business Segments (2014)
  • Roche's Sales and Net Income (2010-2014)
  • Novartis Revenue by Business Segments (2014)
  • Novartis Revenues (2010-2014)
  • Siemens Revenue by Business Segments (2014)
  • Siemens Revenue and Net Income (2010-2014)

List of Tables

  • Stages of Breast Cancer
  • New Breast Cancer Cases and Deaths in the U.S. (2015E)
  • The U.S. MBC Market Revenue Model (2011-2015E)
  • Number of Deaths from Breast Cancer in Brazil
  • New Breast Cancer Cases and Deaths in the Europe (2014)
  • European MBC Market (2011-2015E)
  • CDK4/6 Inhibitors in Clinical Development
  • Side Effects of Aromatase Inhibitors Reported by Women
  • Comparison of Drugs Approved for HR Positive Breast Cancer
  • Comparison of P13 Kinases in Clinical Development
  • J&J's R&D Expenses by Segment (2013 & 2014)
Back to Top